Gyre Therapeutics (GYRE) to Announce Earnings on Monday

Posted by Francis Steltz on Aug 3rd, 2026

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Gyre Therapeutics to post earnings of ($0.08) per share and revenue of $26.49 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Gyre Therapeutics Stock Up 3.0%

Shares of GYRE stock traded up $0.17 during mid-day trading on Monday, reaching $5.92. The stock had a trading volume of 8,932 shares, compared to its average volume of 91,159. The firm’s 50 day simple moving average is $6.21 and its 200 day simple moving average is $7.12. Gyre Therapeutics has a one year low of $5.44 and a one year high of $9.42. The firm has a market cap of $660.24 million, a PE ratio of -66.08 and a beta of 1.92.

Insider Buying and Selling at Gyre Therapeutics

In related news, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the transaction, the chief operating officer owned 700,000 shares in the company, valued at $4,305,000. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ying Luo sold 10,136 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the sale, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 32,535 shares of company stock valued at $219,580. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after acquiring an additional 1,996 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after purchasing an additional 89,390 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $111,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Gyre Therapeutics has an average rating of “Hold” and a consensus price target of $17.00.

View Our Latest Research Report on Gyre Therapeutics

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

Earnings History for Gyre Therapeutics (NASDAQ:GYRE)

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.